Creabilis hires chief medical officer
Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer
Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.
At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.
In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.
You may also like
Pharmaceutical
ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research
ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Pharmaceutical
Asahi Kasei expands Sonanos portfolio with next-generation excipients for injectable drug formulation
Asahi Kasei has introduced two new speciality grades in its Sonanos excipient line designed to enhance sustained release and solubility in injectable drugs and plans GMP-compliant production by 2027
Manufacturing
Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia
Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea